Tislelizumab (Mechanism of Action)
Tislelizumab, marketed under the brand name Tevimbra, is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, a crucial checkpoint in the immune system. By inhibiting PD-1, tislelizumab helps to boost the body’s immune response against cancer cells. Here are some key details about tislelizumab:
Mechanism of Action
Tislelizumab works by blocking the interaction between PD-1 on immune cells and its ligands PD-L1 and PD-L2 on tumor cells. This blockade prevents the tumor from evading immune detection, thereby allowing the immune system to target and destroy cancer cells more effectively.